Incarceration offers the opportunity to improve treatment outcomes of HIV-infected detainees; ensuring that these individuals maintain virologic suppression after release is a major challenge.
The epidemic of incarceration in the U.S., like the HIV epidemic, disproportionately affects blacks — particularly black men, who have more than a one in four chance of being incarcerated at some point in life. It is thus not surprising that one sixth of HIV-infected individuals cycle through correctional facilities annually and that HIV prevalence among inmates is threefold higher than in the community. HIV-infected prison inmates receive medical care, including antiretroviral therapy (ART), but what are the outcomes of such treatment?
To explore this question, investigators conducted a retrospective review involving individuals incarcerated in a Connecticut Department of Correction facility for ≥90 consecutive days between March 1, 2005, a…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)